Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RU84687
- Development stage
- Unknown
- Lead developer
- Sanofi
- Modality
- Small Molecules
01
Overview
RU84687 is an experimental small molecule compound that functions as a subnanomolar and selective binder to the SH2 domain of the Src proto-oncogene tyrosine-protein kinase. By mimicking phosphotyrosine, it inhibits the protein-protein interactions mediated by the Src SH2 domain, thereby blocking Src-dependent signaling pathways. Chemically, it is a phosphonotyrosinamide derivative with the formula C31H34N3O8P. While it is a potent tool for biochemical research into tyrosine kinase signaling, RU84687 has no recorded history of clinical development or therapeutic use in humans.
- Other names
- N-acetyl-N-[1-(1,1'-biphenyl-4-ylmethyl)-2-oxoazepan-3-yl]-3-formyl-O-phosphonotyrosinamide
02
Targets
SRC (Proto-oncogene tyrosine-protein kinase Src)
Beyond the preview
Go deeper on RU84687.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RU84687.